regulatory-affairs-head

FDA submission pathway analysis evaluates device classification to determine whether a 510(k), PMA, or De Novo pathway is optimal. Structured decision frameworks assess device risk and intended use to define the most efficient regulatory route for market access.

EU MDR compliance documentation preparation requires technical file assembly, clinical evaluation planning, and conformity assessment checks. Structured workflows coordinate global market access by identifying necessary regulatory documentation and verifying compliance with European medical device requirements.

Yes, global market access coordination supports simultaneous FDA and EU MDR submissions. The regulatory strategy development process maps overlapping documentation requirements and identifies parallel submission tracks to streamline dual market launches for HealthTech and MedTech devices.

Compliance checks for Class II medical devices involve verifying FDA 510(k) substantial equivalence requirements and EU MDR conformity assessment criteria. Pathway analysis identifies applicable standards and documentation gaps to ensure regulatory readiness across both jurisdictions.

Regulatory strategy development should begin during early device design to identify classification, submission requirements, and testing needs. Initiating pathway analysis early prevents costly documentation gaps and aligns product development with FDA and EU MDR expectations.

Yes, submission management covers FDA De Novo pathways alongside 510(k) and PMA. Pathway analysis evaluates whether a novel device qualifies for the De Novo route and structures the documentation preparation accordingly.